Welcome to our dedicated page for Else Nutrition H news (Ticker: BABYD), a resource for investors and traders seeking the latest updates and insights on Else Nutrition H stock.
Else Nutrition Holdings Inc. (BABYD) is a publicly traded food and nutrition company focused on plant-based products for infants, toddlers, children, and adults, as well as hospital-grade infant feeding accessories. The BABYD news page on Stock Titan aggregates company announcements and media coverage so readers can follow developments in its plant-based nutrition strategy and institutional infant feeding business.
News for Else Nutrition often highlights progress in childhood nutrition products and international expansion. Company releases describe its plant-based, non-soy formula as a clean-ingredient alternative to dairy-based formulas and report on milestones for its Plant-Based Complete Nutrition for Toddlers, made from whole foods such as almonds, buckwheat, and tapioca. Coverage may also include updates on retailer support, consumer feedback, and recognition from industry awards and rankings.
Another key theme in BABYD news is institutional and hospital-related activity. Else Nutrition reports multi-year tender renewals with Israel's largest Health Fund for baby feeding accessories, including sterile and non-sterile baby bottles and disposable nipples supplied to hospitals and maternity wards. Articles may discuss how these tenders affect the company’s Israeli business unit and its role in hospital-grade infant feeding solutions.
Investors can also expect financing and capital markets updates, such as announcements of convertible security funding agreements, warrant issuances, and conditional approvals from the Toronto Stock Exchange for additional share listings. By reviewing BABYD news, readers can track how Else Nutrition communicates its growth plans, funding arrangements, and product positioning in the plant-based nutrition and infant feeding accessories markets.
Else Nutrition (TSX:BABY / OTC PINK:BABYD) announced that CEO Hamutal Yitzhak will present at the Q4 Investor Summit Virtual on December 9, 2025 at 9:30 AM ET. The company said the CEO will also host 1x1 meetings with qualified investors during the conference.
Webcasting will be available via the Else Nutrition webcasting link, and investors can request access to presentations, transcripts and 1-on-1 meetings through the provided access link.
Else Nutrition (OTC: BABYD) announced it was re-awarded a five-year tender by Israel's largest Health Fund to supply sterile and non-sterile baby bottles and disposable nipples to hospitals and maternity wards nationwide, securing continued institutional supply through 2030. The renewal covers institutional distribution and represents approximately 7% of Else's 2024 revenue, removing a potential revenue risk from its Israeli business unit. Production is handled by established third-party manufacturers in Europe and Asia and shipments use independent logistics providers. The company framed the renewal as confirmation of its hospital-grade quality and reliability.
ELSE NUTRITION HOLDINGS (TSX: BABY; OTC: BABYD) entered a convertible security funding agreement with Lind Global Fund III LP to raise up to US$1,280,000 in staged draws. On initial closing the company will issue a US$420,000 Initial Convertible Security (net proceeds US$337,750 after discount/fees) with a 24‑month maturity, monthly convertibility (1/20th per month) and a post‑180‑day company Buy‑Back Right with a 5% premium.
The financing includes detached warrants (2,069,781 First Warrants at 130% of 5‑day VWAP, 48‑month expiry) and TSX conditional approval to list up to 10,582,354 additional shares; converted shares will be subject to a four‑month lockup and resale/short‑sale restrictions. Proceeds are for production and working capital.
FAQ
What is the current stock price of Else Nutrition H (BABYD)?
